Partnering On An Innovative Hydrogel-Based Treatment For Glioblastoma
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor; most patients have a life expectancy of less than 16 months when diagnosed. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments for this aggressive cancer in high demand. TargTex, a European biotech company, is developing a hydrogel-based pharmaceutical product to target GBM. However, the first prototype hydrogel was ineffective in stopping recurrences due to the formulation's limited dosing capabilities
TargTex is now collaborating with Nanoform to enhance its formulation using Nanoform's nanoparticle technology. Applying Nanoform's proprietary CESS® technology is enabling a fivefold increase in drug load compared to nanomilling and has demonstrated deep brain penetration by the drug API. Learn more about the new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs and the GMP-scalable formulation for this promising therapeutic.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.